Investing in dividend stocks is a great strategy for many reasons, including the potential they offer you to significantly ...

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

The Food and Drug Administration today approved Eli Lilly’s weight-loss treatment, Zepbound, for obstructive sleep apnea, ...

The FDA has approved Eli Lillys Zepbound as the first weight-loss drug to treat obstructive sleep apnea, reshaping care for ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking it the first ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 471.82% and ...

FedEx Corp shares increased 9% in Friday's premarket session after the package delivery company outlined plans to spin off its FedEx Freight trucking business Eli Lilly s ...

The FDA has declared the end of the two-year shortages of Eli Lilly's Mounjaro and Zepbound — used to treat diabetes and weight loss, respectively — and has reaffirmed its decision to halt the ...